Source: Kapitales Research

Highlights

• FY26 revenue guidance revised downward to AU$82–87 million due to Energy Services pressure and project timing shifts.
• The company reported its third straight quarter of positive underlying EBITDA, totaling AU$1.1 million, alongside continued margin expansion.
• Rum Jungle project revenue deferred to FY27, while cost reductions and operational improvements remain on track.

SciDev Ltd (ASX: SDV) declined 25.675%, with its share price falling by AU$0.047 to AU$0.137. The sharp decline follows the company’s 3Q FY26 trading update, which highlighted improved profitability but a downgrade to revenue guidance driven by external headwinds.

Profitability Improves Despite Revenue Pressure

The company delivered its third consecutive quarter of positive underlying EBITDA, reaching AU$1.1 million in 3Q FY26 and AU$2.2 million year-to-date. EBITDA margins improved to 6% during the quarter, reflecting the impact of cost optimisation initiatives implemented earlier in the financial year.

Revenue Guidance Revised on External Factors

FY26 revenue guidance has been revised to AU$82–87 million from prior expectations of AU$100–110 million. The downgrade is primarily attributed to intensified competition within commoditized chemical markets, driven by cost-cutting measures among upstream energy clients, alongside reduced demand for higher-margin specialty products.

Project Timing Shifts Impact Near-Term Revenue

Adverse weather conditions in the Northern Territory and global shipping disruptions have delayed progress on the Rum Jungle project. As a result, a meaningful portion of expected revenue has been deferred into FY27 rather than lost, indicating timing-related impacts rather than structural weakness.

Operational Progress Supports Medium-Term Outlook

Despite near-term challenges, core segments such as Process Chemistry continue to perform strongly and are on track for record revenues. Cost reductions, including a 19% decrease in corporate expenses and structural efficiency initiatives, are expected to support improved earnings momentum into FY27.

Outlook Hinges on Execution and Market Recovery

SciDev’s outlook remains tied to recovery in energy sector demand and execution of deferred projects. While profitability trends are improving, sustained revenue growth will depend on market conditions and successful conversion of its operational pipeline into realised income.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au